Skip to content

Contact +44 (0) 20 7060 7474 email us

Johnson & Johnson

Johnson & Johnson

PharmaVitae Profile

Publication Date July 2008
Publisher Datamonitor
Product Type Report
Pages 145
ISBN Number not applicable
Product Code DAT01153

Price

£1,980.00
approximately: $2,998 | €2,210

pdf

Buy Now

print £2,010 ($3,043 | €2,243)

Buy Now

Order above formats by FAX

Order by Fax

Summary

Introduction

This analysis examines the historical and forecast performance for J&J in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Johnson & Johnson's performance against key rivals in the ethical pharmaceutical sector
  • Analyze how J&J will implement life cycle management strategies across its portfolio as a means to combat patent expiries and generic competition
  • Assess J&J's diverse healthcare offering and how this will act to maintain operating growth despite flat forecast revenue expansion for Rx pharma

Contents

  • CHAPTER 1 ABOUT THIS PROFILE
    • Executive summary
    • Quarterly news update
    • Company introduction
    • Company sales
    • Company financials
    • Key products and competitors
    • Data sourcing
    • Sales data
    • Analyst consensus
  • CHAPTER 2 EXECUTIVE SUMMARY
    • Key findings
    • Prescription pharmaceutical sales performance, 2001-13
    • Financial performance, 2001-13
    • J&J: PharmaVitae forecasts at a glance
    • Strategic insight
    • Managing the boom & bust of 'blockbuster' drugs
    • US small molecule drug sales increase generic exposure
    • Lifecycle management will minimize loss from key products
    • Despite challenges, J&J's outlook appears robust
    • Performance to 2013 will be clear by 2010
    • Diversified business balances risk
    • Wide range of strategic options to seek growth
    • SWOT analysis
    • Strengths
    • Weaknesses
    • Opportunities
    • Threats
  • CHAPTER 3 QUARTERLY NEWS UPDATE
    • Product developments
    • Deals and alliances
    • Product deals
    • Technology deals
    • M&A activity
    • Company announcements
    • Future product milestones
  • CHAPTER 4 COMPANY INTRODUCTION
    • Key findings
    • Company overview
    • Company history
    • Company structure
    • M&A history
    • M&A strategy
  • CHAPTER 5 COMPANY SALES
    • Key findings
    • Prescription pharmaceutical sales and growth rate analysis, 2001-13
    • Product analysis
    • Product analysis, 2001-07
    • Product analysis, 2007-13
    • Therapy area analysis
    • Therapy area analysis, 2001-07
    • Therapy area analysis, 2007-13
    • Therapy area focus, 2001-13
    • Geographic analysis
    • Geographic analysis, 2001-07
    • Geographic analysis, 2007-13
    • Geographic focus, 2001-13
    • Launch/core/expiry analysis
    • Explanation of launch/core/expiry analysis
    • Launch analysis, 2007-13
    • Core analysis, 2007-13
    • Expiry analysis, 2007-13
    • Launch/core/expiry configuration, 2007-13
    • Molecule type analysis
    • Molecule type analysis, 2001-07
    • Molecule type analysis, 2007-13
    • Externalization analysis
    • Externalization analysis, 2001-07
    • Externalization analysis, 2007-13
  • CHAPTER 6 COMPANY FINANCIALS
    • Key findings
    • Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2001-07
    • Financial statements, 2001-07
    • Profit and loss account, 2001-07
    • Balance sheet, 2001-07
    • Operating costs and profit analysis
    • Operating costs and profit analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2001-07
    • Operating cost ratio and profit margin analysis, 2007-13
    • Operating costs and profit analysis, 2007-13
    • Return on capital employed analysis
    • Capital employed analysis, 2001-07
    • Return on capital employed (RoCE) analysis, 2001-07
    • Market capitalization analysis
    • Market capitalization analysis, 2001-07
    • Total shareholder returns (TSR) analysis, 2001-07
  • CHAPTER 7 KEY PRODUCTS AND COMPETITORS
    • Key findings
    • Overview
    • Product profiles
    • Risperdal franchise
    • Overview
    • Sales forecast
    • Success driven by first to market and favorable side effect profile
    • US generics hit Risperdal sales from H2 2008
    • Additional products aimed at retaining patients within JNJ's portfolio
    • Invega franchise
    • Overview
    • Sales forecast
    • Switching before launch of generic Risperdal is critical
    • Paliperidone palmitate will build upon Risperdal Consta's success
    • Remicade
    • Overview
    • Sales forecast
    • J&J markets Remicade in the US only
    • Humira has slowed growth of Remicade sales
    • New launches will maintain the growth of J&J's I&I franchise
    • Procrit/ Eprex
    • Overview
    • Sales forecast
    • Decline as market share lost to Aranesp from 2002
    • Safety concerns have hit the wider ESA market
    • Further competition limited to ex-US markets for now
    • Topamax
    • Overview
    • Sales forecast
    • Generics set to erode key US market across 2008-09
    • Sales growth has been supported by use in further indications
    • Rivaroxaban
    • Overview
    • Sales forecast
    • US launch forecast in 2009
    • Set to revolutionize anticoagulant management
    • Attractive product profile ensures market success
    • Velcade
    • Overview
    • Sales forecast
    • Growth driven by label expansion
    • Takeda prevented J&J from acquiring Millennium
    • Prezista
    • Overview
    • Sales forecast
    • Growth strengthened by earlier use
    • Close fit with additional HIV products
  • CHAPTER 8 APPENDIX
    • R&D pipeline
    • References
    • Abbreviations
    • Historical growth rate analysis
  • List of Tables
    • Table 1: J&J - PharmaVitae forecasts at a glance
    • Table 2: Key events set to shape J&J's outlook to 2013
    • Table 3: J&J key product developments, Q1 2008
    • Table 4: J&J product deals and alliances, Q1 2008
    • Table 5: J&J technology deals and alliances, Q1 2008
    • Table 6: J&J M&A activity, Q1 2008
    • Table 7: J&J company announcements,Q1 2008
    • Table 8: J&J future product milestones 2008-2010
    • Table 9: J&J product portfolio overview, sales ($m), 2001-07
    • Table 10: J&J product portfolio overview, sales ($m), 2007-13
    • Table 11: J&J therapy portfolio overview, sales ($m), 2001-07
    • Table 12: J&J therapy portfolio overview, sales ($m), 2007-13
    • Table 13: J&J portfolio overview by geographic region, sales ($m), 2001-07
    • Table 14: J&J portfolio overview by geographic region, sales ($m), 2007-13
    • Table 15: J&J launch portfolio overview ($m), 2007-13
    • Table 16: J&J core portfolio overview ($m), 2007-13
    • Table 17: J&J expiry portfolio overview ($m), 2007-13
    • Table 18: J&J portfolio overview by molecule type ($m), 2001-07
    • Table 19: J&J product portfolio overview by molecule type ($m), 2007-13
    • Table 20: J&J product portfolio overview by source ($m), 2001-07
    • Table 21: J&J product portfolio overview by source ($m), 2007-13
    • Table 22: Total J&J sales by business unit ($m), 2001-07
    • Table 23: J&J profit and loss account ($m), 2001-07
    • Table 24: J&J balance sheet ($m), 2001-07
    • Table 25: J&J operating revenue/cost analysis ($m), 2001-07
    • Table 26: J&J operating cost ratio analysis (% of total revenue), 2001-07
    • Table 27: J&J operating profit analysis by segment (% of segment sales), 2001-07
    • Table 28: J&J operating cost ratio analysis (% of total revenue), 2007-13
    • Table 29: J&J operating revenue/cost analysis ($m), 2007-13
    • Table 30: J&J capital employed ($m), 2001-07
    • Table 31: J&J EBIT return on capital employed ($m), 2001-07
    • Table 32: J&J EBIT pre-tax return/Capital employed driver analysis ($m), 2001-07
    • Table 33: J&J market capitalization ($ billion), 2001-07
    • Table 34: J&J total shareholder returns (annual %), 2001-07
    • Table 35: Key products overview, 2007-13
    • Table 36: Risperdal: overview
    • Table 37: Risperdal franchise: sales forecast ($m), 2007-13
    • Table 38: Invega: overview
    • Table 39: Invega franchise: sales forecast ($m), 2007-13
    • Table 40: Remicade: overview
    • Table 41: Remicade: sales forecast ($m), 2007-13
    • Table 42: Procrit: overview
    • Table 43: Procrit: sales forecast ($m), 2007-13
    • Table 44: Topamax: overview
    • Table 45: Topamax: sales forecast ($m), 2007-13
    • Table 46: Rivaroxaban: overview
    • Table 47: Rivaroxaban: sales forecast ($m), 2007-13
    • Table 48: Velcade: overview
    • Table 49: Velcade: sales forecast ($m), 2007-13
    • Table 50: Prezista: overview
    • Table 51: Prezista: sales forecast ($m), 2007-13
    • Table 52: J&J's late-stage R&D pipeline
    • Table 53: J&J contributions to year-on-year growth (%), 2001-07
  • List of Figures
    • Figure 1: J&J prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 2: J&J financial performance ($m), 2001-13
    • Figure 3: Lifecycle management strategies boost key J&J franchises, 2001-13 ($m)
    • Figure 4: J&J's strategic options for growth
    • Figure 5: SWOT analysis of J&J
    • Figure 6: J&J company structure
    • Figure 7: Recent & major M&A/ divestment activity, J&J
    • Figure 8: Johnson & Johnson prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13
    • Figure 9: J&J key sales growth driver & resistors ($m), 2001-07
    • Figure 10: J&J key sales growth drivers & resistors ($m), 2007-13
    • Figure 11: J&J prescription pharmaceutical sales by therapy area ($m), 2001-13
    • Figure 12: J&J prescription pharma sales by therapy area, (% of total), 2001-13
    • Figure 13: J&J prescription pharmaceutical sales by geographic region ($m), 2001-13
    • Figure 14: J&J drivers and resistors by geographic region, sales ($m), 2001-07
    • Figure 15: J&J drivers and resistors by geographic region, sales ($m), 2007-13
    • Figure 16: J&J prescription pharmaceutical sales by geographic region (% of total), 2001-13
    • Figure 17: J&J launch/core/expiry configuration ($m), 2007-13
    • Figure 18: J&J prescription pharmaceutical sales by molecule type ($m), 2001-13
    • Figure 19: J&J growth drivers & resistors by molecule type ($m), 2007-13
    • Figure 20: J&J prescription pharmaceutical sales by source ($m), 2001-13
    • Figure 21: J&J growth drivers & resistors by source ($m), 2001-07
    • Figure 22: J&J growth drivers & resistors by source ($m), 2007-13
    • Figure 23: J&J operating revenue/cost analysis ($m), 2001-13
    • Figure 24: J&J operating cost ratio analysis (% of total revenue), 2001-13
    • Figure 25: J&J return on capital employed, EBIT margin and capital turnover, 2001-07
    • Figure 26: Return on capital employed formula
    • Figure 27: J&J market capitalization ($ billion), 2001-07
    • Figure 28: J&J total shareholder returns (annual %), 2001-07
    • Figure 29: US atypical antipsychotic market share by USD, 2003-07
    • Figure 30: J&J's antipsychotic franchise, global sales ($m), 2003-13